Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Concizumab Prophylaxis in Hemophilia A or B Without Inhibitors
KCT0004556Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of concizumab in hemophilia A, hemophilia B (HB), sponsored by Novo Nordisk. Started May 2020; status: active, not recruiting.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on KCT0004556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004556.